Data gathered: November 17
AI Stock Analysis - Intellia Therapeutics (NTLA)
Analysis generated July 24, 2024. Powered by Chat GPT.
Intellia Therapeutics, Inc. (NTLA) is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. The company was founded in 2014 and has since embarked on a journey to transform treatment paradigms for diseases with high unmet medical needs. With a robust pipeline and strategic partnerships, Intellia aims to drive innovation and bring CRISPR-based therapies to market.
Stock Alerts - Intellia Therapeutics (NTLA)
 |
Intellia Therapeutics | November 15 Price is down by -5.6% in the last 24h. |
|
Intellia Therapeutics | November 14 Price is down by -6.7% in the last 24h. |
|
Intellia Therapeutics | November 12 Price is down by -5.7% in the last 24h. |
|
Intellia Therapeutics | November 11 Price is up by 5.1% in the last 24h. |
Alternative Data for Intellia Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 45,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 29 | Sign up | Sign up | Sign up |
| Patents | 50 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 1,230 | Sign up | Sign up | Sign up |
| Reddit Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 48 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,551 | Sign up | Sign up | Sign up |
| Twitter Followers | 11,345 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 37 | Sign up | Sign up | Sign up |
| Linkedin Employees | 590 | Sign up | Sign up | Sign up |
About Intellia Therapeutics
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
| Price | $13.97 |
| Target Price | Sign up |
| Volume | 3,660,000 |
| Market Cap | $1.42B |
| Year Range | $13.97 - $29.54 |
| Dividend Yield | 0% |
| Analyst Rating | 81% buy |
| Industry | Biotechnology |
In the news
 |
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from BrokeragesNovember 16 - ETF Daily News |
Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin AmyloidosisNovember 15 - Finnhub |
|
|
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Boosted by Axxcess Wealth Management LLCNovember 14 - ETF Daily News |
 |
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In FocusNovember 10 - SeekingAlpha |
 |
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their EstimatesNovember 8 - Yahoo |
 |
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...November 8 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 9.1M | 31M | -21M | -136M | 0 | -1.340 |
| Q2 '24 | 7M | 32M | -25M | -147M | -136M | -1.520 |
| Q1 '24 | 29M | 31M | -2.2M | -107M | -111M | -1.120 |
| Q4 '23 | -1.9M | 29M | -30M | -132M | -137M | -1.460 |
| Q3 '23 | 13M | 29M | -16M | -122M | -131M | -1.380 |
Insider Transactions View All
| Dube Michael P filed to sell 47,012 shares at $19. October 4 '24 |
| Clark Eliana filed to sell 71,470 shares at $22.9. July 3 '24 |
| Verwiel Frank filed to sell 17,948 shares at $25. June 20 '24 |
| Clark Eliana filed to sell 71,470 shares at $33. March 5 '24 |
| BASTA JAMES filed to sell 81,571 shares at $33. March 5 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Thomas Carper Democrat |
Sep 5, 23 | Sell | $1K - $15K |
| Thomas Carper Democrat |
Jun 30, 23 | Buy | $1K - $15K |
Read more about Intellia Therapeutics (NTLA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Intellia Therapeutics?
The Market Cap of Intellia Therapeutics is $1.42B.
What is the current stock price of Intellia Therapeutics?
Currently, the price of one share of Intellia Therapeutics stock is $13.97.
How can I analyze the NTLA stock price chart for investment decisions?
The NTLA stock price chart above provides a comprehensive visual representation of Intellia Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Intellia Therapeutics shares. Our platform offers an up-to-date NTLA stock price chart, along with technical data analysis and alternative data insights.
Does NTLA offer dividends to its shareholders?
As of our latest update, Intellia Therapeutics (NTLA) does not offer dividends to its shareholders. Investors interested in Intellia Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Intellia Therapeutics?
Some of the similar stocks of Intellia Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.